Innoviva (INVA) Share-based Compensation (2010 - 2026)
Innoviva (INVA) posted Share-based Compensation of $101000.0 for Q1 2026, down 99.56% on a QoQ basis from $22.7 million in Q4 2025, and down 95.3% year-over-year from $2.1 million in Q1 2025.
Innoviva (INVA) Share-based Compensation (2010 - 2026) Analysis & Trends
Innoviva's Share-based Compensation history runs 17 years deep, the most recent figure standing at $101000.0 for Q1 2026.
- Quarterly Share-based Compensation fell 95.3% year-over-year to $101000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (up 102.73% YoY) and the FY2025 annual result came in at $22.7 million, up 64.09% from the prior year.
- Share-based Compensation was $101000.0 for Q1 2026 at Innoviva, down from $22.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $22.7 million in Q4 2025 and bottomed at -$23000.0 in Q1 2023.
- A 5-year average of $3.9 million and a median of $1.2 million in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 6415.69% — and 2023, when it tumbled 110.75%.
- Innoviva's Share-based Compensation stood at $8.7 million in 2022, then climbed by 9.15% to $9.5 million in 2023, then soared by 45.72% to $13.9 million in 2024, then jumped by 64.09% to $22.7 million in 2025, then plunged by 99.56% to $101000.0 in 2026.
- Business Quant data shows INVA's Share-based Compensation at $101000.0 in Q1 2026, $22.7 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | 101,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101,000.00 |
| Mar 31, 2026 | 101,000.00 |
| Dec 31, 2025 | 22.74 Mn |
| Dec 31, 2025 | 22.74 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Dec 31, 2024 | 13.86 Mn |
| Dec 31, 2024 | 13.86 Mn |
| Sep 30, 2024 | 211,000.00 |
| Sep 30, 2024 | 211,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Mar 31, 2024 | 404,000.00 |
| Mar 31, 2024 | 404,000.00 |
| Dec 31, 2023 | 9.51 Mn |
| Dec 31, 2023 | 9.51 Mn |